Bilfinger SE (ETR:GBF)

Regulus Therapeutics Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	532.7	465	538.4	573.4	642.9	510.6
Short-Term Investments	-	68.5	228.3	42.5	218.5	478.8
Cash & Short-Term Investments	532.7	533.5	766.7	615.9	861.4	989.4
Cash Growth	19.31%	-30.42%	24.48%	-28.50%	-12.94%	84.25%
Accounts Receivable	1,348	1,322	1,137	1,048	879.2	834.6
Other Receivables	15.9	37.5	25.8	18.6	26.2	28.6
Receivables	1,363	1,365	1,162	1,067	905.4	863.2
Inventory	112.7	115.1	87.3	80.8	64.9	59.8
Prepaid Expenses	-	29.1	24.4	19.9	26.8	21.3
Other Current Assets	93.7	21.3	10.5	6.8	8.8	9.2
Total Current Assets	2,103	2,064	2,051	1,790	1,867	1,943
Property, Plant & Equipment	469.8	470.8	406.5	414.7	431.4	456
Long-Term Investments	22.1	18.8	16.1	16.1	14.3	29.9
Goodwill	-	792.3	783	783	777.7	761.5
Other Intangible Assets	816	20.5	4.8	3.3	2.8	3.4
Long-Term Deferred Tax Assets	85.7	87.4	87.9	35.9	46.7	55.8
Other Long-Term Assets	-0.1	6.6	4.6	5.6	5.2	3.4
Total Assets	3,496	3,464	3,357	3,052	3,149	3,256
Accounts Payable	1,020	494.1	444.6	427.7	337.2	298.4
Accrued Expenses	-	249.1	213.8	208.9	195.1	217.4
Current Portion of Long-Term Debt	60.3	1.8	263.2	6.8	9.3	0.3
Current Portion of Leases	-	57.5	50.7	47.9	45	46.6
Current Income Taxes Payable	35.9	35.4	25.5	29.7	21.9	23.9
Current Unearned Revenue	-	350	249	227.1	157.2	159.7
Other Current Liabilities	426.5	332.8	338.7	370.1	365	425
Total Current Liabilities	1,543	1,521	1,586	1,318	1,131	1,171
Long-Term Debt	309.6	175.3	175.4	255.7	255.2	375
Long-Term Leases	-	142	119.5	133.2	139.9	146.3
Long-Term Deferred Tax Liabilities	22.9	21.9	16	10.8	4.2	2.9
Other Long-Term Liabilities	25.2	26.1	18.8	17.2	23.2	22.2
Total Liabilities	2,152	2,152	2,176	1,974	1,860	2,058
Common Stock	1,331	132.6	132.6	132.6	132.6	132.6
Retained Earnings	-	552.3	441.2	432.1	599.3	673.5
Treasury Stock	-	-2.5	-3.5	-104.7	-12.2	-149.5
Comprehensive Income & Other	-	618.5	602.8	627.9	581.1	552.7
Total Common Equity	1,331	1,301	1,173	1,088	1,301	1,209
Minority Interest	12.8	10.4	8.4	-9.7	-11.8	-10.7
Shareholders' Equity	1,344	1,311	1,182	1,078	1,289	1,199
Total Liabilities & Equity	3,496	3,464	3,357	3,052	3,149	3,256
Total Debt	369.9	376.6	608.8	443.6	449.4	568.2
Net Cash (Debt)	162.8	156.9	157.9	172.3	412	421.2
Net Cash Growth	73.75%	-0.63%	-8.36%	-58.18%	-2.18%	-
Net Cash Per Share	4.32	4.16	4.20	4.33	10.06	10.32
Filing Date Shares Outstanding	37.62	37.52	37.48	37.41	40.72	40.3
Total Common Shares Outstanding	37.62	37.52	37.48	37.41	40.72	40.3
Working Capital	559.9	543.1	465.8	471.9	736.6	771.6
Book Value Per Share	35.38	34.67	31.30	29.08	31.95	30.01
Tangible Book Value	514.8	488.1	385.3	301.6	520.3	444.4
Tangible Book Value Per Share	13.68	13.01	10.28	8.06	12.78	11.03
Land	-	203.7	161.2	180.4	192.9	243.3
Machinery	-	854.4	734.3	734.5	728.6	748.6
Order Backlog	-	4,120	3,385	3,226	2,946	2,585

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.